Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude multicentrique, en double aveugle, contrôlée par placebo, évaluant l'innocuité et l'efficacité de l'IRX4204 dans le psoriasis en plaques

7 novembre 2026 mis à jour par: Io Therapeutics

Une étude de 4 semaines, multicentrique, en double aveugle, contrôlée par placebo évaluant l'innocuité et l'efficacité du composé agoniste RXR IRX4204 pour le traitement du psoriasis en plaques léger à modéré

The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are:

  • Does IRX4204 treat plaque psoriasis symptoms?
  • Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated?
  • What medical problems do participants have when taking IRX4204?

Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis.

Participants will:

  • Take IRX4204 every day for 28 days
  • Visit the clinic once every week for checkups and tests
  • Complete specific assessments about plaque psoriasis and changes to plaques

Aperçu de l'étude

Statut

Suspendu

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Texas
      • Webster, Texas, États-Unis, 77598
        • Not posted

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. At least 18 years of age

  2. Have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study treatment

  3. Meet the following disease severity criteria for moderate to severe plaque psoriasis at Screening and Baseline visits:

    1. IGA Score of 3 or 4 AND
    2. Total affected body surface area of >3 to 10% for moderate and 10% to 15% for severe psoriasis
    3. Excludes participants with scalp only plaques
  4. Be inadequately controlled with or intolerant of at least one prior topical therapy including but not limited to: corticosteroids, retinoids, vitamin D, vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, tapinarof, roflumilast for the treatment of psoriasis at both Screening and Baseline visits

  5. In the opinion of the Investigator, be a candidate for phototherapy or systemic treatment for psoriasis

  6. Completed appropriate washouts for prior treatments for psoriasis

  7. Be considered, in the opinion of the Investigator, suitable candidates for RXR agonist therapy

  8. Women participants of childbearing potential (WOCBP) (see Section 8.1.10) or sexually active male participants with partners of childbearing potential agree to practice a highly effective method of contraception (failure rate of < 1% per year when used consistently and correctly; see Section 8.1.10.1) prior to receiving, while receiving, and for at least 6 months after receiving the last administration of study intervention

  9. WOCBP must have a negative highly sensitive serum beta-human chorionic gonadotropic (b-hCG) pregnancy test at Screening and confirmed at Baseline prior to receiving the first administration of study drug

  10. WOCBP must agree not to donate eggs (ova, oocytes) or freeze for future and males must agree not to donate sperm for the purpose of reproduction for at least 6 months after receiving the last administration of study intervention.

  11. Female participants must agree to not breastfeed while enrolled in this study and within 6 months after the last dose of study intervention

  12. Sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

  13. Be willing to and able to adhere to the requirements in this protocol

Exclusion Criteria:

  1. Has more than 15% of total body surface area affected by psoriasis plaques
  2. Has a non-plaque form of psoriasis (e.g., erythrodermic, guttate, or pustular) at Screening or at time of randomization
  3. Has current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
  4. Has confounding diagnoses including but not limited to palmoplantar pustulosis, eczematous dermatitis, contact/irritant dermatitis, acquired keratoderma
  5. Has received within 12 weeks of the first dose (Day 1) any prior biologic (or biosimilars of) for the treatment of psoriasis, psoriatic arthritis, or any other indications that could impact the assessment of psoriasis. Prior biologic therapy includes but is not limited to TNF-inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors
  6. Has received within 4 weeks of the first dose (Day 1) any systemic immunosuppressives for the treatment of psoriasis or psoriatic arthritis, or any other indications that could impact the assessment of psoriasis, Phototherapy or narrow band laser (e.g., Excimer or XTRAC), lithium, antimalarials, or intramuscular (IM) gold. Systemic immunosuppressive therapy includes but is not limited to methotrexate, azathioprine, cyclosporine, JAK/TYK pathway inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, acitretin, or anakinra
  7. Has received within 2 weeks of the first dose (Day 1) any topical medications for psoriasis or other conditions that could impact assessment of psoriasis, including but not limited to topical corticosteroids, retinoids, vitamin D analogs, combinations of calcipotriene and topical corticosteroids, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, PDE4 inhibitors (e.g. crisaborole), or other topicals used for the treatment of psoriasis (tapinarof, roflumilast etc.)
  8. Has received within 12 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) other biologic therapy or experimental antibody, any agent that modulates T-cells (e.g., natalizumab, abatacept etc.)
  9. Has received within 4 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) any other experimental systemic therapy for any indication
  10. Is currently enrolled in another study using an investigational agent or procedure
  11. Has evidence of skin conditions that could interfere with clinical assessments of psoriasis (e.g. eczema, seborrheic dermatitis, or pityriasis rosea)
  12. Has a current history of severe, uncontrolled or progressive systemic medical conditions including renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  13. Has unstable cardiovascular disease, defined as a recent clinical deterioration in the last 3 months (e.g., unstable angina, atrial fibrillation) or a cardiac hospitalization within the last 3 months
  14. Currently has a known malignancy or has a history of malignancy within 5 years before screening with the exception of non-melanoma skin cancer curatively treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ of the cervix that has been treated with no evidence of recurrence for at least 3 years before the first study drug administration
  15. Has a history of lymphoproliferative disease, including lymphoma, leukemia, monoclonal gammopathy, or signs/symptoms suggestive of possible lymphoproliferative disease
  16. Has a transplanted organ (with the exception of a corneal transplant > 3 months before the first study drug administration)
  17. Has unstable suicidal ideation or suicidal behavior, or a suicide attempt (including interrupted, aborted attempts and preparatory behaviors for suicide attempt), in the last 6 months
  18. Has had a major surgery within 8 weeks of Screening or has such surgery planned during the time participant is expected to participate in the study
  19. Has had a substance abuse problem within the previous 12 months
  20. Has a history of chronic or recurrent infectious disease including but not limited to chronic renal infection, recurrent urinary tract infection (UTI), chronic respiratory infections (e.g., tuberculosis), skin infections, or fungal infections
  21. Is currently being treated for a thyroid condition or have abnormalities in TSH, free T4 or T3 at Screening
  22. Has had a serious infection (e.g., sepsis, pneumonia, pyelonephritis) requiring hospitalization within the 2 months before Screening
  23. Has had herpes zoster (shingles) within 2 months prior to Screening
  24. Has an active tuberculosis (TB) infection as confirmed by TB test during screening
  25. Tests positive for hepatitis B virus (HBV) infection
  26. Is seropositive for antibodies to hepatitis C virus (HCV). If the antibody test result is positive at screening, the participant will be allowed to be re-screened one time and enrolled after a negative HCV RNA test result
  27. Is infected with human immunodeficiency virus (HIV)
  28. Unable to avoid prolonged sun exposure or use of tanning beds or other ultraviolet light sources
  29. Has received within 2 weeks of the first dose (Day 1) any prescribed anticoagulant, including but not limited to coumarins (such as warfarin), factor Xa inhibitors (i.e., apixaban, rivaroxaban), heparins (e.g., heparin, enoxaparin), and direct thrombin inhibitors
  30. Has any condition that, in the opinion of the Investigator, would make participation not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
  31. Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator
  32. Any abnormal laboratory value greater than 2.5 times upper limit of normal (ULN). If one or more of the laboratory parameters is out of range, a single retest of laboratory values is permitted

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo

Placebo

Placebo

Comparateur actif: Treatment

IRX4204

Active Treatment

Autres noms:
  • NRX194204
  • IRX4204Psoriasis

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo
Délai: Baseline (Day 1) to Day 42

Percentage of participants achieving an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at Day 28 with at least a 2-grade improvement from Baseline to end of study.

Baseline (Day 1) to Day 42

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
To evaluate if participants receiving IRX4204 have greater improvement in participant reported outcomes when compared to participants receiving placebo
Délai: from Baseline (Day 1) to Day 28

Change in Daily Quality of Life Index (DLQI) score will be evaluated. The DLQI is calculated by adding the score of each question, resulting in a minimum of 0 to a maximum of 30. The higher the score, the more quality of life is impaired.

from Baseline (Day 1) to Day 28
To evaluate if participants receiving IRX4204 experience a greater reduction in affected Body Surface Area when compared to participants receiving placebo
Délai: from Baseline (Day 1) to Day 28

Percent change in affected Body Surface Area (BSA) from Baseline to end of treatment will be evaluated. The body surface area refers to the total amount of skin on the body that is covered by psoriasis lesions and used to assess the severity of the condition. A higher percentage indicates a more severe case of psoriasis.

from Baseline (Day 1) to Day 28
To evaluate if a greater proportion of participants receiving IRX4204 achieve PASI50, PASI75 and PASI90 when compared to participants receiving placebo
Délai: from Baseline (Day 1) to End of Study (Day 42)

Proportion of participants to achieve PASI50 (50% or greater improvement from Baseline), PASI75, and PASI90 to the end of the study will be evaluated. Achieving PASI 50, PASI 75, and PASI 90 indicates different levels of improvement in psoriasis severity as measured by the Psoriasis Area and Severity Index (PASI) score, with PASI 50 indicating a 50% reduction from baseline, PASI 75 signifying a 75% reduction, and PASI 90 representing a 90% reduction in psoriasis symptoms. Higher PASI numbers signifying increasingly clearer skin.

from Baseline (Day 1) to End of Study (Day 42)
To evaluate if participants receiving IRX4204 achieve greater improvement from baseline in disease and symptom severity as measured by the Psoriasis Area and Severity Index (PASI).
Délai: from Baseline (Day 1) to End of Treatment (Day 28)

Change From Baseline to Day 28 in mean Psoriasis Area and Severity Index (PASI) score of participants receiving IRX4204 compared to placebo.

from Baseline (Day 1) to End of Treatment (Day 28)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Incidence of Treatment Emergent and Serious Adverse Events
Délai: from Baseline (Day 1) to End of Study (Day 42)

The number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and the number of participants who experienced TEAEs and SAEs will also be tabulated to evaluate the safety profile of IRX4204.

from Baseline (Day 1) to End of Study (Day 42)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 mars 2027

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

4 décembre 2024

Première soumission répondant aux critères de contrôle qualité

4 décembre 2024

Première publication (Réel)

9 décembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner